{"meshTagsMajor":["Mutation"],"meshTags":["Animals","Colorectal Neoplasms","Humans","Mutation","Receptor, ErbB-2"],"meshMinor":["Animals","Colorectal Neoplasms","Humans","Receptor, ErbB-2"],"genes":["ERBB2","ERBB2","anti-EGFR","ERBB2"],"publicationTypes":["Comment","Journal Article","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov\u0027t"],"abstract":"ERBB2 mutations and amplifications are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefit from ERBB2-directed therapy.","title":"ERBB2 emerges as a new target for colorectal cancer.","pubmedId":"26243861"}